Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maisel Urges Caution In Adoption Of Atritech’s Watchman Anti-Stroke Device

This article was originally published in The Gray Sheet

Executive Summary

If approved by FDA, Atritech's Watchman left-atrial appendage occluder should not be routinely implanted in atrial fibrillation patients to prevent strokes until more is known about the long-term safety and efficacy of the device, according to cardiologist and device safety expert William Maisel
Advertisement

Related Content

Left Atrial Appendage Closure Studies: FDA Offers Tips
Boston Scientific Buys Atritech For Watchman Stroke Prevention Device
Boston Scientific Buys Atritech For Watchman Stroke Prevention Device
Atritech's Watchman anti-stroke device requires further study
Atritech's Watchman anti-stroke device requires further study
Panel Endorses Atritech Watchman Stroke-Prevention Device In Close Vote
Panel Endorses Atritech Watchman Stroke-Prevention Device In Close Vote

Topics

Advertisement
UsernamePublicRestriction

Register

MT027506

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel